Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children
Author(s) -
Anna Turkova,
Ellen White,
Hilda Mujuru,
Adeodata Kekitiinwa,
Cissy Kityo,
Avy Violari,
Abbas Lugemwa,
Tim R. Cressey,
Philippa Musoke,
Ebrahim Variava,
Mark F. Cotton,
Moherndran Archary,
Thanyawee Puthanakit,
Osee Behuhuma,
Robin Kobbe,
Steven B. Welch,
Mutsa BwakuraDangarembizi,
Pauline Amuge,
Elizabeth Kaudha,
Linda BarlowMosha,
Shafic Makumbi,
Nastassja Ramsagar,
Chaiwat Ngampiyaskul,
Godfrey Musoro,
Lorna Atwine,
Afaaf Liberty,
Victor Musiime,
Dickson Bbuye,
Grace Miriam Ahimbisibwe,
Suwalai Chalermpantmetagul,
Shabinah S. Ali,
Tatiana Sarfati,
Ben Wynne,
Clare Shakeshaft,
Angela Colbers,
Nigel Klein,
Sarah Bernays,
Yacine Saïdi,
Alexandra Coelho,
Tiziana Grossele,
Alexandra Compagnucci,
Carlo Giaquinto,
Pablo Rojo,
Deborah Ford,
Diana M. Gibb
Publication year - 2021
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa2108793
Subject(s) - dolutegravir , medicine , efavirenz , confidence interval , integrase inhibitor , human immunodeficiency virus (hiv) , antiretroviral therapy , randomized controlled trial , pediatrics , viral load , virology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom